News und Analysen
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at
Sensorion to Host a Symposium during ISIET’s International Conference on Inner Ear Therapies on April 26, 2025
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
Sartorius Stedim Biotech publishes unaudited first quarter results for 2025
Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2025 financial results on Wednesday, May 7th, before the market opens. A conference call has been scheduled to
Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to seven new employees.
On April 9
Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced donations totaling $1.5 million to multiple patient assistance
EQS-News: Eckert & Ziegler Proposes Dividend of € 0.50 for FY 2024
Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24
Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2025 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 24
EQS-News: Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
EQS-Adhoc: FamiCord AG significantly exceeds annual earnings guidance for 2024 on the basis of preliminary figures
Premier, Inc. to Report Fiscal 2025 Third-Quarter Results and Host Conference Call on May 6, 2025
Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2025 third quarter on Tuesday, May 6, 2025, at approximately 6:30 a.m. ET. The company will also
Siegfried shareholders approve all proposals at Annual General Meeting 2025
EQS-News: Eckert & Ziegler: US Consul Visits Radiopharmaceutical Production in Braunschweig
Natus Sensory verstärkt Führungsteam mit Ernennungen in Schlüsselpositionen
Natus Sensory freut sich, die Erweiterung seines globalen Führungsteams um drei erfahrene Führungskräfte bekannt zu geben. Damit bekräftigt das Unternehmen sein Engagement für die Förderung von
Natus Sensory Strengthens Executive Team with Key Leadership Appointments
Natus Sensory is pleased to announce the addition of three accomplished executives to its global leadership team, reinforcing the company’s commitment to advancing innovation, customer impact, and
EQS-News: Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Form 8.3 - The Vanguard Group, Inc.: PureTech Health plc
GenSight Biologics Announces the Filing of its 2024 Universal Registration Document
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Viatris, Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) and reminds investors of the June
Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced encore presentations of top-line data from the pivotal, Phase 3
GenSight Biologics Reports Cash Position as of March 31, 2025, and Provides Business Update
Regulatory News:
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it has entered into a license agreement with Eli Lilly and Company (“Lilly”), allowing Lilly to leverage
Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time.
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 1, 2025. Management will hold a conference call to
Lonza Publishes Invitation to the 2025 Annual General Meeting and 2024 Annual and Sustainability Reports